UK Launches Inquiry Into Its Clinical Trials Problems After Pharma Outcry
Ex-Health Minister To Report Back In Spring
Stung by criticism from the AstraZeneca and GSK CEOs, the UK government has launched an independent review into clinical trials in the hopes of reversing a steep decline.
You may also be interested in...
AstraZeneca’s Soriot: UK’s Pharma Policies Have Already Hit Investment
Pascal Soriot claims the UK is undermining its life sciences sector, and the government needs to support market access and clinical trials in the country or face losing out to competing nations.
Worsening UK Pharma Sector Close To ‘Tipping Point,’ Warns GSK Chief
Dame Emma Walmsley has delivered a broadside to the UK government, urging it to reverse a raised revenues ‘clawback’ for pharma companies and boost new medicines uptake in order to maintain the UK’s competitiveness in life sciences.
Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy
Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.